Join the Hypogonadism group to help and get support from people like you.
Hypogonadism News
Testosterone Treatment Does Not Cut Fracture Incidence in Men With Hypogonadism
THURSDAY, Jan. 18, 2024 – Testosterone treatment does not result in a lower incidence of clinical fractures among middle-aged and older men with hypogonadism, according to a study published in the...
FDA Approves Kyzatrex (testosterone undecanoate) for the Treatment of Male Hypogonadism
RALEIGH, N.C., Aug. 02, 2022 (GLOBE NEWSWIRE) – Marius Pharmaceuticals, a patient-centric healthcare company, today announced the approval of Kyzatrex (testosterone undecanoate) by the U.S. Food and...
FDA Approves Tlando (testosterone undecanoate) for Male Hypogonadism
EWING, N.J., March 29, 2022 (GLOBE NEWSWIRE) – Antares Pharma, Inc., (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration g...
FDA Approves Jatenzo (testosterone undecanoate) for Certain Forms of Hypogonadism
March 27, 2019 – The U.S. Food and Drug Administration today approved Jatenzo (testosterone undecanoate), an oral testosterone capsule to treat men with certain forms of hypogonadism. These men have...
FDA Approves Xyosted (testosterone enanthate) Injection for Testosterone Replacement Therapy in Adult Males
EWING, N.J., Oct. 01, 2018 (GLOBE NEWSWIRE) – Antares Pharma, Inc. (NASDAQ:ATRS) today announced the approval of Xyosted (testosterone enanthate) injection by the U.S. Food and Drug Administration...
FDA Approves Aveed (testosterone undecanoate) Injectable Testosterone Replacement Therapy
DUBLIN, March 6, 2014 /PRNewswire/ – Endo International plc announced today that its operating company Endo Pharmaceuticals Inc. received U.S. Food and Drug Administration (FDA) approval of Aveed...